Quantcast

Latest William K. Oh Stories

2014-06-15 08:20:51

LONDON, June 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Hormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/drug_discovery/hormone_refractory_breast_cancer_global_clinical_trials_review_h1_2014.htmlHormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2014 SummaryGlobalData's clinical trial report, "Hormone Refractory Breast Cancer Global Clinical Trials...

2014-04-15 08:28:19

Phase III Trial Now Recruiting Patients SANTA ROSA, Calif., April 15, 2014 /PRNewswire/ -- A phase III clinical trial conducted at the Meir Medical Center in Kfar-Saba, Israel is now recruiting participants to study the effects of dietary supplement PectaSol-C® modified citrus pectin (MCP) in controlling prostate specific antigen (PSA) levels in prostate cancer patients. "MCP has shown activity against prostate and other cancers in a number of previous studies, and toxicology...

2014-04-12 23:00:02

ResearchMoz.us include new market research report "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" to its huge collection of research reports.Full Report With TOC at http://www.researchmoz.us/metastatic-hormone-refractory-castration-resistant-androgen-independent-prostate-cancer-pipeline-review-h1-2014-report.html. Albany, NY (PRWEB) April 13, 2014 Researchmoz presents this most up-to-date research on...

2014-04-08 12:30:37

-- Peak US urology organisation CUSP Group, LLC to evaluate MiStat(TM) technology SYDNEY, April 8, 2014 /PRNewswire/ -- Private Australian biotechnology company Minomic International Ltd will launch two overseas trials of its MiStat(TM) prostate cancer screening test, following an agreement with the prestigious CUSP Group, LLC a Uro-Oncology Trials Management Organisation in the United States. An initial pilot study to be launched in April will examine 300 patient samples and is...

2014-02-11 08:30:37

BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 11, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the pre-specified number of events required for final analysis of the Phase 3 SYNERGY trial has been reached. The primary efficacy endpoint of SYNERGY will analyze overall survival benefit for custirsen in combination with standard first-line docetaxel chemotherapy and prednisone in men with metastatic castrate-resistant prostate cancer...

2014-01-30 08:31:31

Multiple Studies of Decipher Prostate Cancer Classifier Presented at 2014 ASCO Genitourinary Symposium SAN DIEGO, Jan. 30, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced new data demonstrating that its Decipher® Prostate Cancer Classifier, a genomic test capable of predicting the probability of developing metastatic prostate cancer, outperformed existing clinical risk factors for predicting biochemical failure and distant metastasis following radiation therapy. In addition,...

2013-09-24 11:18:06

Analysis of patient subset from RTOG 9202 A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. Men with advanced prostate...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related